{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:23:28Z","timestamp":1790637808939,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA193651"],"award-info":[{"award-number":["CA193651"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41375-022-01558-5","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T07:04:15Z","timestamp":1649660655000},"page":"1499-1507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-4237","authenticated-orcid":false,"given":"Kimberly","family":"Bodaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Barthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Landrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triona Ni","family":"Chonghaile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Devidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-3957","authenticated-orcid":false,"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6860-798X","authenticated-orcid":false,"given":"Jules P.","family":"Meijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-9013","authenticated-orcid":false,"given":"Anthony","family":"Letai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0249-9007","authenticated-orcid":false,"given":"Alejandro","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"1558_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541\u201352.","journal-title":"N Engl J Med"},{"key":"1558_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJM197601292940503","volume":"294","author":"I Tsukimoto","year":"1976","unstructured":"Tsukimoto I, Wong KY, Lampkin BC. Surface markers and prognostic factors in acute lymphoblastic leukemia. N Engl J Med. 1976;294:245\u20138.","journal-title":"N Engl J Med"},{"key":"1558_CR3","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S0140-6736(77)90361-0","volume":"2","author":"JM Chessells","year":"1977","unstructured":"Chessells JM, Hardisty RM, Rapson NT, Greaves MF. Acute lymphoblastic leukaemia in children: classification and prognosis. Lancet. 1977;2:1307\u20139.","journal-title":"Lancet."},{"key":"1558_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.V55.3.395.395","volume":"55","author":"SE Sallan","year":"1980","unstructured":"Sallan SE, Ritz J, Pesando J, Gelber R, O\u2019Brien C, Hitchcock S, et al. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980;55:395\u2013402.","journal-title":"Blood."},{"key":"1558_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjh.15983","volume":"186","author":"M Hofmans","year":"2019","unstructured":"Hofmans M, Suciu S, Ferster A, Van Vlierberghe P, Mazingue F, Sirvent N, et al. Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL). Br J Haematol. 2019;186:741\u201353.","journal-title":"Br J Haematol"},{"key":"1558_CR6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol. 2012;30:1663\u20139.","journal-title":"J Clin Oncol"},{"key":"1558_CR7","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","volume":"21","author":"JM Goldberg","year":"2003","unstructured":"Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21:3616\u201322.","journal-title":"J Clin Oncol"},{"key":"1558_CR8","doi-asserted-by":"crossref","first-page":"e28719","DOI":"10.1002\/pbc.28719","volume":"68","author":"MA Burns","year":"2021","unstructured":"Burns MA, Place AE, Stevenson KE, Gutierrez A, Forrest S, Pikman Y, et al. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021;68:e28719.","journal-title":"Pediatr Blood Cancer"},{"key":"1558_CR9","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","volume":"34","author":"R Pieters","year":"2016","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591\u2013601.","journal-title":"J Clin Oncol"},{"key":"1558_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","volume":"15","author":"A Vora","year":"2014","unstructured":"Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15:809\u201318.","journal-title":"Lancet Oncol"},{"key":"1558_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","volume":"16","author":"CH Pui","year":"2015","unstructured":"Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015;16:465\u201374.","journal-title":"Lancet Oncol"},{"key":"1558_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/leu.2016.234","volume":"31","author":"CH Pui","year":"2017","unstructured":"Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C, et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia 2017;31:333\u20139.","journal-title":"Leukemia"},{"key":"1558_CR13","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1200\/JCO.2012.47.0500","volume":"31","author":"K Schmiegelow","year":"2013","unstructured":"Schmiegelow K, Levinsen MF, Attarbaschi A, Baruchel A, Devidas M, Escherich G, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2013;31:2469\u201376.","journal-title":"J Clin Oncol"},{"key":"1558_CR14","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3109\/10428194.2011.639018","volume":"53","author":"E Blanco","year":"2012","unstructured":"Blanco E, Beyene J, Maloney AM, Almeida R, Ethier MC, Winick N, et al. Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis. Leuk Lymphoma. 2012;53:878\u201385.","journal-title":"Leuk Lymphoma"},{"key":"1558_CR15","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.2011.37.3217","volume":"29","author":"ML te Winkel","year":"2011","unstructured":"te Winkel ML, Pieters R, Hop WC, de Groot-Kruseman HA, Lequin MH, van der Sluis IM, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2011;29:4143\u201350.","journal-title":"J Clin Oncol"},{"key":"1558_CR16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJM199103213241205","volume":"324","author":"SE Lipshultz","year":"1991","unstructured":"Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808\u201315.","journal-title":"N Engl J Med"},{"key":"1558_CR17","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","volume":"22","author":"K Nguyen","year":"2008","unstructured":"Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Leukemia. 2008;22:2142\u201350.","journal-title":"Leukemia."},{"key":"1558_CR18","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","volume":"28","author":"RH Ko","year":"2010","unstructured":"Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a therapeutic advances in Childhood Leukemia Consortium Study. J Clin Oncol. 2010;28:648\u201354.","journal-title":"J Clin Oncol"},{"key":"1558_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","volume":"366","author":"M Schrappe","year":"2012","unstructured":"Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012;366:1371\u201381.","journal-title":"N Engl J Med"},{"key":"1558_CR20","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1084\/jem.20180570","volume":"215","author":"IM Aries","year":"2018","unstructured":"Aries IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, et al. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018;215:3094\u2013114.","journal-title":"J Exp Med"},{"key":"1558_CR21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.1206727","volume":"334","author":"T Ni Chonghaile","year":"2011","unstructured":"Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334:1129\u201333.","journal-title":"Science."},{"key":"1558_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","volume":"151","author":"TT Vo","year":"2012","unstructured":"Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012;151:344\u201355.","journal-title":"Cell."},{"key":"1558_CR23","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1172\/JCI82908","volume":"126","author":"PD Bhola","year":"2016","unstructured":"Bhola PD, Mar BG, Lindsley RC, Ryan JA, Hogdal LJ, Vo TT, et al. Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. J Clin Invest. 2016;126:3827\u201336.","journal-title":"J Clin Invest"},{"key":"1558_CR24","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","volume":"16","author":"AE Place","year":"2015","unstructured":"Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O\u2019Brien JE, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16:1677\u201390.","journal-title":"Lancet Oncol"},{"key":"1558_CR25","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/pbc.25470","volume":"62","author":"SS Winter","year":"2015","unstructured":"Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015;62:1176\u201383.","journal-title":"Pediatr Blood Cancer"},{"key":"1558_CR26","doi-asserted-by":"publisher","first-page":"29022","DOI":"10.1074\/jbc.M115.670224","volume":"290","author":"E Losdyck","year":"2015","unstructured":"Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, et al. Distinct acute lymphoblastic leukemia (ALL)-associated Janus Kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK inhibitor specificities. J Biol Chem. 2015;290:29022\u201334.","journal-title":"J Biol Chem"},{"key":"1558_CR27","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1182\/blood-2014-04-566687","volume":"124","author":"S Degryse","year":"2014","unstructured":"Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124:3092\u2013100.","journal-title":"Blood."},{"key":"1558_CR28","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/leu.2016.83","volume":"30","author":"K Cante-Barrett","year":"2016","unstructured":"Cante-Barrett K, Spijkers-Hagelstein JA, Buijs-Gladdines JG, Uitdehaag JC, Smits WK, van der Zwet J, et al. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia. 2016;30:1832\u201343.","journal-title":"Leukemia."},{"key":"1558_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1182\/blood-2017-07-797597","volume":"131","author":"S Degryse","year":"2018","unstructured":"Degryse S, Bornschein S, de Bock CE, Leroy E, Vanden Bempt M, Demeyer S, et al. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. Blood. 2018;131:421\u20135.","journal-title":"Blood."},{"key":"1558_CR30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1200\/JCO.2016.69.6278","volume":"35","author":"D O\u2019Connor","year":"2017","unstructured":"O\u2019Connor D, Moorman AV, Wade R, Hancock J, Tan RM, Bartram J, et al. Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2017;35:660\u20137.","journal-title":"J Clin Oncol"},{"key":"1558_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157\u201363.","journal-title":"Nature."},{"key":"1558_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147\u201356.","journal-title":"Lancet Oncol"},{"key":"1558_CR33","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1200\/JCO.2010.28.3390","volume":"28","author":"A Gutierrez","year":"2010","unstructured":"Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, et al. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3816\u201323.","journal-title":"J Clin Oncol"},{"key":"1558_CR34","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, et al. Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125:1759\u201367.","journal-title":"Blood."},{"key":"1558_CR35","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","volume":"35","author":"J Bond","year":"2017","unstructured":"Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, et al. Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a Group for Research on Adult Acute Lymphoblastic Leukemia Study. J Clin Oncol. 2017;35:2683\u201391.","journal-title":"J Clin Oncol"},{"key":"1558_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet."},{"key":"1558_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"1558_CR38","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616\u201324.","journal-title":"N Engl J Med"},{"key":"1558_CR39","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","volume":"302","author":"PS Changelian","year":"2003","unstructured":"Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875\u20138.","journal-title":"Science."},{"key":"1558_CR40","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","volume":"11","author":"JB Telliez","year":"2016","unstructured":"Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11:3442\u201351.","journal-title":"ACS Chem Biol"},{"key":"1558_CR41","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/art.41316","volume":"72","author":"MF Robinson","year":"2020","unstructured":"Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, et al. Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2020;72:1621\u201331.","journal-title":"Arthritis Rheumatol"},{"key":"1558_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127\u201332.","journal-title":"Nat Biotechnol"},{"key":"1558_CR43","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.molcel.2016.02.019","volume":"61","author":"PD Bhola","year":"2016","unstructured":"Bhola PD, Letai A. Mitochondria-judges and executioners of cell death sentences. Mol Cell. 2016;61:695\u2013704.","journal-title":"Mol Cell"},{"key":"1558_CR44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","volume":"129","author":"T Girardi","year":"2017","unstructured":"Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and molecular biology of T-ALL. Blood . 2017;129:1113\u201323.","journal-title":"Blood"},{"key":"1558_CR45","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1038\/sj.onc.1202796","volume":"18","author":"S Dumon","year":"1999","unstructured":"Dumon S, Santos SC, Debierre-Grockiego F, Gouilleux-Gruart V, Cocault L, Boucheron C, et al. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene. 1999;18:4191\u20139.","journal-title":"Oncogene."},{"key":"1558_CR46","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1158\/2159-8290.CD-12-0504","volume":"3","author":"T Sanda","year":"2013","unstructured":"Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013;3:564\u201377.","journal-title":"Cancer Discov"},{"key":"1558_CR47","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1365-2567.2009.03244.x","volume":"130","author":"N Chetoui","year":"2010","unstructured":"Chetoui N, Boisvert M, Gendron S, Aoudjit F. Interleukin-7 promotes the survival of human CD4+ effector\/memory T cells by up-regulating Bcl-2 proteins and activating the JAK\/STAT signalling pathway. Immunology. 2010;130:418\u201326.","journal-title":"Immunology."},{"key":"1558_CR48","first-page":"823","volume":"9","author":"K Takada","year":"2009","unstructured":"Takada K, Jameson SC. Naive T cell homeostasis: from awareness of space to a sense of place. Nat Rev. 2009;9:823\u201332.","journal-title":"Nat Rev"},{"key":"1558_CR49","doi-asserted-by":"publisher","first-page":"11671","DOI":"10.1074\/jbc.272.18.11671","volume":"272","author":"T Ito","year":"1997","unstructured":"Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem. 1997;272:11671\u20133.","journal-title":"J Biol Chem"},{"key":"1558_CR50","doi-asserted-by":"publisher","first-page":"26865","DOI":"10.1016\/S0021-9258(18)47099-8","volume":"269","author":"WS May","year":"1994","unstructured":"May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem. 1994;269:26865\u201370.","journal-title":"J Biol Chem"},{"key":"1558_CR51","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1073\/pnas.97.4.1578","volume":"97","author":"X Deng","year":"2000","unstructured":"Deng X, Ruvolo P, Carr B, May WS Jr. Survival function of ERK1\/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA. 2000;97:1578\u201383.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1558_CR52","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/leu.2017.276","volume":"32","author":"S Degryse","year":"2018","unstructured":"Degryse S, de Bock CE, Demeyer S, Govaerts I, Bornschein S, Verbeke D, et al. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK\/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2018;32:788\u2013800.","journal-title":"Leukemia."},{"key":"1558_CR53","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","volume":"13","author":"TC Yeh","year":"2007","unstructured":"Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor. Clin Cancer Res. 2007;13:1576\u201383.","journal-title":"Clin Cancer Res"},{"key":"1558_CR54","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074\u201387.","journal-title":"Cancer Discov"},{"key":"1558_CR55","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351\u201365.","journal-title":"Cancer Cell"},{"key":"1558_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.gde.2008.01.004","volume":"18","author":"JA Engelman","year":"2008","unstructured":"Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev. 2008;18:73\u20139.","journal-title":"Curr Opin Genet Dev"},{"key":"1558_CR57","doi-asserted-by":"crossref","unstructured":"Bliss CI. The calculation of microbial assays. Bacteriol Rev. 1956;20:243\u201358.","DOI":"10.1128\/br.20.4.243-258.1956"},{"key":"1558_CR58","doi-asserted-by":"publisher","first-page":"e1002200","DOI":"10.1371\/journal.pmed.1002200","volume":"13","author":"Y Li","year":"2016","unstructured":"Li Y, Buijs-Gladdines JG, Cante-Barrett K, Stubbs AP, Vroegindeweij EM, Smits WK, et al. IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study. PLoS Med. 2016;13:e1002200.","journal-title":"PLoS Med"},{"key":"1558_CR59","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1038\/leu.2017.136","volume":"31","author":"C Delgado-Martin","year":"2017","unstructured":"Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, et al. JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31:2568\u201376.","journal-title":"Leukemia."},{"key":"1558_CR60","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1038\/s41375-021-01291-5","volume":"35","author":"JCG van der Zwet","year":"2021","unstructured":"van der Zwet JCG, Buijs-Gladdines J, Cordo V, Debets DO, Smits WK, Chen Z, et al. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia. 2021;35:3394\u2013405.","journal-title":"Leukemia."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01558-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01558-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01558-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T21:25:34Z","timestamp":1700429134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01558-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01558-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SPH has received consulting fees from Novartis, honoraria from Amgen, Jazz Pharmaceuticals and Servier, and owns common stock in Amgen. LBS has received research funding from Novartis. DTT has served on advisory boards for BEAM Therapeutics, Janssen, and Sobi and receives research funding from Neoimmune Tech and BEAM Therapeutics. AL receives research support from AbbVie, AstraZeneca and Novartis, and is a cofounder and equity holder in Flash Therapeutics and Vivid Bioscience. AG receives research support from Astellas Pharma and is on an advisory board of Attivare Therapeutics. The authors have no other relevant conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}